Summary by Futu AI
Tempus AI reported strong Q3 2025 financial results with total revenue increasing 85% year-over-year to $334.2 million, driven by 117% growth in Genomics revenue to $252.9 million and 26% growth in Data and services revenue to $81.3 million. The company achieved positive adjusted EBITDA of $1.5 million, compared to negative $21.8 million in Q3 2024.The company completed several strategic initiatives during the quarter, including a $750 million convertible senior notes offering and the acquisition of Paige.AI for $102.7 million to expand its digital pathology capabilities. Additionally, Tempus raised $195.5 million through an at-the-market equity offering and repaid $276.9 million of term loan facility debt.Looking ahead, Tempus maintains a strong liquidity position with $660.5 million in cash and cash equivalents as of quarter-end. The company continues to invest in expanding its genomics testing capabilities, data analytics platform, and artificial intelligence applications while pursuing strategic acquisitions to accelerate growth in key markets.
